Federal grant · project grant (b)
Novel Glucose Responsive Insulin for Improved Treatment of Diabetes - Summary/abstract. Diabetes Is Rapidly Becoming a Global Health Crisis. Depending on the Type of Statistical Methodology Used, the World-wide Incidence of the Most Common Type of Diabetes, Adult-onset or Type Ii, Is Estimated to Be in the Range of 285 Million. in Both Type I and Type Ii Diabetics Glycemic Control Is Paramount as the Inability to Maintain Glycemic Control Results in Several Secondary Complications Including Neuropathy, Nephropathy and Retinopathy, That Often Lead to Amputations, Dialysis and Blindness as Well as Increased Risk of Cardiovascular Complications. for the Majority of Diabetics Glycemic Control Requires Constant Vigilance and Monitoring of Blood Glucose Levels. the Overarching Goal of This Project Is the Development of a Novel Glucose Responsive Insulin (GRI) With a Reversible, Glucose Dependent Response at the Insulin Receptor. the Full Realization of the Gri Concept Would Most Closely Mimic the Benefits of a Healthy Pancreas and Maintain Euglycemia, Reduce/eliminate the Need for Constant Monitoring, and Ultimately, Reduce/eliminate the Complications of Diabetes. the Scope of This Proposal Is the Design and Testing of a Series of Analogs That Can Bind Glucose Allosterically and Demonstrate Differential Response at the Insulin Receptor. This Will Be Achieved Through Completion of Three Aims. in Aim 1 We Will Use a Novel Computational Platform to Design and Produce a Series of Gris With Glucose Binding Affinity in the Physiological Range. in Aim 2 We Will Determine the Glucose Binding Affinity of the Analogues Produced in Aim 1. Finally, in Aim 3 We Will Measure the Insulin Receptor (IR) and Insulin Like Growth Factor (IGF-R1) Affinity of the Gri’s in the Presence of Glucose at Physiological Concentrations. Completion of These Aims Will Result in the Identification of Several Gri Lead Candidates With Glucose Binding in the Physiological Range and Reversible Glucose Dependent Insulin Receptor Binding and Absence of IGF-1R Binding.
Committed
$300,000
Paid out
$219.2K
73%
Committed, not yet paid
$80.8K
27%
Loading…
Everything here is this single award's whole record — signed, amended, paid — not a fiscal-year slice. The by-year charts elsewhere split an award across the years it was committed; this page keeps it whole.
Committed is what the government has legally promised on this award so far. Contracts can also carry a ceiling — the maximum if every option is exercised. Unspent ceiling is headroom, not money owed.
The cash actually disbursed against this award. The gap from committed is the disbursement pipeline: promised, not yet cashed.
Each transaction is a signing event — an action that created or changed the award, dated the day it was signed — not a payment. Negative amounts are real: money de-committed at closeout or renegotiation.
One bar, the award’s whole arithmetic: paid out, then committed, not yet paid, then unspent ceiling.